Seeking Alpha

More on Keryx Biopharmaceutical (KERX): Q1 misses on a per share basis due to higher R&D...

More on Keryx Biopharmaceutical (KERX): Q1 misses on a per share basis due to higher R&D expenses, due principally to its KRX-0401 and Zerenex Phase 3 clinical programs. Shares -0.7% AH.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs